Management Team
The Prosensa Management team:
-
Hans GCP Schikan - Chief Executive Officer
Hans GCP Schikan, Chief Executive Officer is responsible for the overall management and strategic direction of Prosensa.
-
Giles Campion - Chief Medical Officer & SVP R&D
Giles Campion, Chief Medical Officer and Senior Vice-President R&D is responsible for the company’s discovery and development strategy and activities.
-
Roelck A Cuperus - VP Regulatory Affairs
Roelck A Cuperus, VP Regulatory Affairs is responsible for the directing worldwide regulatory activities pertaining to the development of oligonucleotides in several diseases.
-
Judith van Deutekom - VP Drug Discovery
Judith van Deutekom, Vice-President Drug Discovery is a molecular biologist and has an extensive 17-year track record in the genetic research of muscular dystrophies.
-
Luc Dochez - Chief Business Officer & SVP Bus. Development
Luc Dochez, Chief Business Officer & SVP Business Development joined Prosensa in November 2008 and is responsible for all business and corporate development activities at the company.
-
Richard H Holslag - VP Manufacturing
Richard H Holslag, VP Manufacturing joined Prosensa in February 2009 and is responsible for all Manufacturing activities.
-
Sjef de Kimpe - VP Early Drug Development
Sjef de Kimpe, Vice-President Early Drug Development is responsible for pre-clinical and early drug development.
-
Berndt Modig - Chief Financial Officer
Berndt Modig is responsible for the financial management and strategy of Prosensa. He has more than 20 years of international experience in finance and operations, private equity and M&A.
-
Harry Relouw - Director Finance & Control
Harry Relouw, Director Finance & Control is responsible for finance and control, procurement and ICT.
